Paris, 29 October 2012– Nanobiotix, a French pioneer in nanomedicine that has developed NanoXray, a revolutionary therapeutic approach for the local treatment of cancer, today celebrated its successful listing on Segment C of NYSE Euronext in Paris.
The company was cofounded in 2003 by Laurent Lévy upon completion of his thesis on nanosemiconductors in the United States. Nanobiotix has since developed a totally new nanoparticles-based approach to the local treatment of cancer, called NanoXray. These nanoparticles enhance the radiotherapy efficacy within the tumour without increasing X-ray induced damage to surrounding healthy tissue. With its 30 Paris-based employees, Nanobiotix has started expanding its footprint internationally, signing its first development partnership in August 2012 with an Asian pharmaceutical company.
Nanobiotix (ticker code: NANO) was listed through the admission to trading of 8,053,880 existing shares and 2,361,607 new shares issued under a Global Offering, with full exercise of the extension clause and the over-allotment option. The Global Offering raised a total of approximately €14.2 million.
The admission and issue price of Nanobiotix shares was set at €6 per share, near the high end of the indicative spread. Market capitalisation stood at around €62.4 million on the day of listing.
“Our European market extends a warm welcome to Nanobiotix, and we are very pleased to be a source of financing for a growth company that challenges the conventional approaches to the treatment of cancer”, said Marc Lefèvre, Head of European Business Development and Client Coverage at NYSE Euronext. “NYSE Euronext in Paris has become the most important market for biotech and medical technology companies in Europe, with 18 transactions and around €430 million raised in the past three years.”
Laurent Lévy, CEO of Nanobiotix, added, “I was delighted by the success of our listing on NYSE Euronext’s regulated market, which gives us a fundamental advantage in terms of visibility. Nanobiotix will now be able to use its enhanced prestige to strengthen its communication strategy, a must if its NanoXray technology is to make inroads into the principal oncology markets.The listing of Nanobiotix on NYSE Euronext is an important step in the development of our company, and I would like to give heartfelt thanks to our partners, new shareholders and employees, who have all contributed to this success. After nearly a decade of research and development efforts we are now more focused than ever on the future and on the revolution taking place in the local treatment of cancer.
To mark its listing, Mr Lévy rang the opening bell of NYSE Euronext’s European market, in the presence of Nanobiotix’s senior managers and employees, its financial and legal partners and the listing team of NYSE Euronext.
The Global Offering was made up of an Open Price Public Offering and a Global Placement with institutional investors in France and other countries.